.

The Effect of Genetic Polymorphism on Therapeutic Response of Metformin in Women with Polycystic Ovarian Syndrome in Iraqi Population

LAUR Repository

Show simple item record

dc.contributor.author Al Shaikhly, Raya
dc.date.accessioned 2022-04-05T11:32:33Z
dc.date.available 2022-04-05T11:32:33Z
dc.date.copyright 2021 en_US
dc.date.issued 2021-01-01
dc.identifier.uri http://hdl.handle.net/10725/13444
dc.description.abstract Insulin resistance and compensatory hyperinsulinemia have been proposed as potential mechanisms for the gonadotropin secretory abnormalities characteristic of PCOS. Thus, metformin, an insulin-lowering agents, has been prescribed extensively to regulate insulin level of patients with PCOS. However, there are individual differences in the treatment effectiveness of metformin among PCOS patients. The exact mechanism of insulin resistance remains to be clarified; however, it is supposed that it originates from the post-receptor defects. The insulin receptor substrate-1 (IRS1) is an important intermediate in insulin signaling pathway. Polymorphisms in IRS1 have been associated with insulin resistance. Respectively, in this study, we investigated the effect of the polymorphisms of IRS1 on the treatment effectiveness of metformin in PCOS patients. The study involved 100 women diagnosed with PCOS according to Rotterdam criteria and 100 control healthy women. All patients diagnosed with PCOS received 500 mg twice daily for 12 weeks. Both case and control group were genotyped for the single nucleotide polymorphisms (SNPs) (rs1801123) of IRS.1.Main outcome measures were hormonal parameters, metabolic parameters, and lipid panel parameters. They were measured at baseline for control and PCOS group and 12 weeks post metformin treatment for PCOS patients only.Our study has shown that metformin had differential effects on fasting insulin level, HbA1C, LH, LH/FSH ratio, testosterone (p-value<0.05)among patients based on different genotypes of IRS.1. Patients with mutated IRS.1 were not showing the same response as patients with intact IRS.1 gene. This finding provides data to support future PCOS clinical trials about Iraqi population, but also shows how genetics and polymorphism can play an important role in explaining how the response of PCOS patients might differ according to a specific type of polymorphism. en_US
dc.language.iso en en_US
dc.subject Metformin -- Therapeutic use en_US
dc.subject Polycystic ovary syndrome -- Treatment en_US
dc.subject Insulin resistance en_US
dc.subject Insulin -- Receptors en_US
dc.subject Women -- Health and hygiene -- Iraq en_US
dc.subject Lebanese American University -- Dissertations Corporate en_US
dc.subject Dissertations, Academic en_US
dc.title The Effect of Genetic Polymorphism on Therapeutic Response of Metformin in Women with Polycystic Ovarian Syndrome in Iraqi Population en_US
dc.type Thesis en_US
dc.term.submitted Fall en_US
dc.author.degree Doctor of Pharmacy en_US
dc.author.school SOP en_US
dc.author.idnumber 200903055 en_US
dc.author.commembers Milane, Aline
dc.author.commembers Kanbar, Roy
dc.author.department Pharmaceutical Sciences en_US
dc.description.physdesc 1 online resource (xi, 53 leaves): col. ill. en_US
dc.author.advisor Mroueh, Mohamad
dc.keywords Polycystic ovarian syndrome (PCOS) en_US
dc.keywords metformin en_US
dc.keywords polymorphism en_US
dc.keywords the insulin receptor substrate-1(IRS.1) en_US
dc.keywords insulin resistance (IR) en_US
dc.keywords Iraqi population en_US
dc.description.bibliographiccitations Includes bibliographical references (leaf 43-53) en_US
dc.identifier.doi https://doi.org/10.26756/th.2022.337
dc.author.email raya.al-shaikhly@lau.edu en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php en_US
dc.publisher.institution Lebanese American University en_US
dc.author.affiliation Lebanese American University en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR


Advanced Search

Browse

My Account